Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PLC Systems -- Ignore unavailable to you. Want to Upgrade?

To: John Martin who wrote (860)	5/6/1998 1:20:00 PM
From: tuck	Read Replies (1) \| Respond to of 1202

Threadsters, Tried a little due diligence yesterday. To whit, I had taken note of the CEO stating that his company believed its competitors used different and fuzzier endpoints (exercise tolerance, I think) in their clinical trials. His drift was that the FDA preferred more objective endpoints such as myocardial perfusion, which was the endpoint PLC has used. So I contacted the IR departments of various competitors and asked if they'd send me a copy of their trial protocols, or at least the endpoints. I have gotten one reply, from one Tara Spangler of Eclipse's IR dept. She said it wasn't public info "at this time" and politely declined to send it to me. So we are left to guess, or try to get it out of a doctor involved. Some centers (and relevant doctors) involved in the trials can be found with a web search. However, my impression is that this is probably a security issue, and the doctors would also not be forthcoming. Anyone out here experienced enough to confirm this? Good luck to all, Tuck P.S. If certain posters do not take offense, I will be happy to post anything that seems interesting from the packet Ms. Spangler is sending me.